AEON Biopharma’s (AEON) Buy Rating Reiterated at HC Wainwright

AEON Biopharma (NASDAQ:AEON)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $18.00 target price on the stock.

AEON Biopharma Stock Down 49.4 %

NASDAQ AEON opened at $1.70 on Monday. The stock has a 50-day moving average of $9.32 and a two-hundred day moving average of $7.62. AEON Biopharma has a 1-year low of $1.38 and a 1-year high of $17.17.

AEON Biopharma (NASDAQ:AEON) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.71) EPS for the quarter. On average, sell-side analysts forecast that AEON Biopharma will post -1.18 EPS for the current year.

Hedge Funds Weigh In On AEON Biopharma

A hedge fund recently bought a new stake in AEON Biopharma stock. Atalaya Capital Management LP acquired a new stake in AEON Biopharma, Inc. (NASDAQ:AEON) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,675,000 shares of the company’s stock, valued at approximately $19,827,000. AEON Biopharma comprises 21.7% of Atalaya Capital Management LP’s holdings, making the stock its biggest position. Atalaya Capital Management LP owned approximately 41.28% of AEON Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). 22.78% of the stock is owned by institutional investors and hedge funds.

About AEON Biopharma

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.